secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-039334
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics FY 2023 net loss $25M vs $14.9M; going concern substantial doubt; $12.5M new financing
--------------------------------------------------------------------------------

- FY 2023 revenue $2.8M (down 58% from $6.7M); net loss $25.0M vs $14.9M in 2022.
- Reserve for credit loss of $5.3M on terminated Prime Capital Ventures credit agreement.
- Completed $2.5M private placement (Feb 2024) and $10.0M secured notes (Mar 2024); substantial doubt about going concern as of Dec 31, 2023.
- Phase 1/1b trials of HCW9218 completed; planning Phase 2 in ovarian and pancreatic cancer.
- Arbitration with Altor/NantCell scheduled for May 2024; new Delaware complaint for contribution of legal fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017024039334/0000950170-24-039334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017024039334/hcwb-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer